Intellia Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Intellia reported positive Phase 3 HAELO data for lonvo-z (in vivo CRISPR for hereditary angioedema): 87% attack reduction vs. placebo over 6 months (0.26 vs. 2.10 mean monthly rate, p<0.0001); 62% attack-free vs. 11% placebo; all secondary endpoints met with p<0.0001. Company expects FDA BLA acceptance in H2 2026 and U.S. commercial launch in H1 2027. Cash position strengthened to $628.4M (up from $605.1M at year-end 2025) via $195M net proceeds from April 2026 equity offering; runway extends at least into 2028. Nex-z Phase 3 enrollment reinitiated; MAGNITUDE-2 completion expected H2 2026. Q2 2026 net loss $106.6M vs. $101.3M prior year.
Why this rating
Positive Phase 3 data + near-term BLA/launch pathway + strengthened balance sheet material for ~$870M biotech; meaningful fraction of company value hinges on lonvo-z approval/commercialization trajectory.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.